Demineralized bone matrix (DBM) compositions, methods of making and methods of treatment with the same are provided. The DBM compositions are made from mechanically entangled bone material that does not contain a carrier. The coherent mass of mechanically entangled demineralized bone fibers can be obtained by needle punching with barbed needles, entanglement with water or air jets, or by applying ultrasonic waves to the demineralized bone fibers. A coherent mass of mechanically entangled demineralized bone fibers can also be obtained by application to demineralized bone fibers of moisture, heat and pressure provided by pressure rollers. A method of making a bone material for hydration with a liquid is also provided. The method includes subjecting demineralized bone fibers to mechanical entanglement to obtain a coherent mass of demineralized bone fibers in the absence of a carrier. A method of treating a bone cavity with a mass of mechanically entangled demineralized bone fibers is also provided. The method of treatment includes implanting into a bone cavity a coherent mass of mechanically entangled demineralized bone fibers, wherein the coherent mass of mechanically entangled demineralized bone fibers does not contain a carrier.

Disclosed are various bioactive and/or biocompatible materials and methods of making the same.

In certain embodiments, the present invention provides the use of microRNA (miR)-200a and/or miR-200c to inhibit ossification and bone formation. In certain embodiments, the present invention provides the use of miR-200a inhibitor to stimulate bone regeneration.

Described herein are medical film materials that incorporate one or more neuro-regenerative drugs into a polymer film. The polymer film includes a copolymer of lactide and caprolactone. The neuro-regenerative drug includes the macrolactam immunosuppressant FK506. The film is configured such that when placed under physiological conditions, the neuro-regenerative drug is released in an extended, substantially linear fashion for a period of at least 30 days.

A material, especially a glassy material of pyrophosphate type, corresponding to the general formula (I): {[(M.sup.2+).sub.1−x(R.sup.+).sub.2x].sub.2[(P.sub.2O.sub.7.sup.4−).sub.1−y(PO.sub.4.sup.3−).sub.4y/3]} n(H.sub.2O) in which x and y are positive rational numbers each between 0 and 0.8, and n is such that the weight percentage of water in the material is greater than 0 and less than or equal to 95. M.sup.2+ represents a bivalent ion of a metal chosen from calcium, magnesium, strontium, copper, zinc, cobalt, manganese and nickel, or any mixture of such bivalent ions. R.sup.+ represents a monovalent ion of a metal selected from potassium, lithium, sodium, and silver, or any mixture of such monovalent ions. This material in particular can be used in manufacturing of bone replacements or prosthesis coatings.

It is an object to provide a therapeutic material for a skin ulcer which has excellent therapeutic effects on intractable skin ulcers such as decubitus ulcers with pockets and huge decubitus ulcers. By applying the therapeutic material for decubitus ulcers consisting of a fibrous material holding an antibiotic and a cell proliferation accelerator therein which is formed into an approximately spherical shape to a site of decubitus in a state in which a defect extending to the dermis, subcutaneous tissue, muscle or bone occurs, it is possible to treat critical skin ulcers such as intractable decubitus ulcers with pockets and huge intractable decubitus ulcers, as well as to treat not only relatively mild decubitus classified as stage II according to the US National Pressure Ulcer Advisory Panel (NPUAP) staging system, i.e., decubitus having ulcers in a state in which a part of the dermis is deficient, but also severe decubitus that has progressed to stage III to IV according to the NPUAP staging system, particularly decubitus with intractable ulcers with pockets or decubitus with huge intractable ulcers.

The present application is directed to the field of scaffolds for tissue engineering. The scaffolds are typically comprised of nanofibers and are optionally biomineralized. The present application provides a process for forming nanofibrous materials via electrospinning and for biomineralizing such materials. The scaffolds of the present application can be biomineralized and contain a plurality of cells either on or within the scaffold, resulting in synthetic, bioresorbable scaffolds that can be used in various biomedical applications, such as for bone regeneration.

This disclosure relates to methods for promoting bone formation or reducing bone destruction. This disclosure also relates to methods for promoting the recruitment of mesenchymal stem cells (MSCs) to a local site of injury or surgical intervention in bone to promote healing. In addition, this disclosure relates to methods for reducing or preventing mineral formation or bone growth, or reducing bone mass. The methods disclosed herein are useful for treating conditions such as osteopetrosis or osteoradionecrosis.

An antibiotic-eluting article for implantation into a mammalian subject, produced by an additive manufacturing process wherein a polymeric material is concurrently deposited with a selected antibiotic. The additive manufacturing process is a fused deposition modeling process. The antibiotic-eluting article may be temporary or permanent orthopaedic skeletal component, an orthopaedic articulating joint replacement component, and/or an external hard-shell casing for an implantable device. One or more bone-growth-promoting compositions may be concurrently deposited with the polymeric material. The implantable device may be a cardiac pacemaker, a spinal cord stimulator, a neurostimulation system, an intrathecal drug pump for delivery of medicants into the spinal fluid, and infusion pump for delivery of chemotherapeutics and or anti-spasmodics, an insulin pump, an osmotic pump, and a heparin pump.

Disclosed in the present invention are an emodin succinyl ester compound, a preparation method therefor and a use thereof, the emodin succinyl ester compound having the structure as represented by formula I (R being a C.sub.1-5 alkyl group). The method provided in the present invention has a simple method course, and may effectively save time in synthesis and reduce costs, being simple to operate, being easy to implement, and being suitable for industrial production. Experiments show that the emodin succinyl ester compound of the present invention may better promote the healing of diabetic wounds than emodin, and may be used for preparing a drug for promoting the healing of diabetic wounds. Moreover, it has been confirmed by means of performing pharmacological experiments on rats suffering from experimentally mixed hyperlipidemia that the emodin succinyl ester compound of the present invention is superior to emodin, and has the advantages of having a remarkable blood fat lowering effect, being safe, being simple and convenient to administer, the raw materials being low cost and readily available, and being easy to transport and store.